Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784928 | 0.88 | LDHA (0.30) | LDHA | |
| SCHEMBL3058542 | 0.83 | NOTUM (0.39) | NOTUMLDHACFTRALDH1A1HPGD | |
| SCHEMBL1583640 | 0.78 | NOTUM (0.41) | NOTUMLDHACFTRALDH1A1HSD17B10 | |
| SCHEMBL3074208 | 0.78 | CFTR (0.48) | NOTUMLDHACFTRALDH1A1HPGD | |
| SCHEMBL1583465 | 0.78 | NOTUM (0.42) | NOTUMLDHACFTRALDH1A1 | |
| SCHEMBL3691065 | 0.77 | CFTR (0.40) | NOTUMLDHACFTRALDH1A1HSD17B10 | |
| SCHEMBL1583159 | 0.77 | NOTUM (0.40) | NOTUMLDHACFTRALDH1A1HSD17B10 | |
| SCHEMBL1584276 | 0.77 | NOTUM (0.38) | NOTUMLDHACFTRALDH1A1HPGD | |
| SCHEMBL3793277 | 0.77 | NOTUM (0.41) | NOTUMLDHACFTRALDH1A1 | |
| SCHEMBL3786834 | 0.76 | NOTUM (0.36) | NOTUMLDHACFTRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | NOTUM 1173/4885LDHA 512/4885CFTR 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.